Analytical validation of Aspyre Clinical Test for Lung (Blood): A multiplexed PCR and pyrophosphorolysis-based assay for detecting actionable NSCLC variants in plasma cfDNA and cfRNA [0.03%]
Aspyre肺癌血液检测试验（临床）的分析验证：一种多重PCR和焦磷酸解链法，用于检测血浆cfDNA和cfRNA中的可操作NSCLC变异型
Ryan Thomas Evans,Katherine Elizabeth Knudsen,Elizabeth Gillon-Zhang et al.
Ryan Thomas Evans et al.
Background: Liquid biopsy is an important non-invasive method of sampling the molecular profile of tumors for patients to access personalized oncology therapeutics but can be challenging. NGS-based methods require high sa...
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience [0.03%]
印度肺癌患者循环肿瘤DNA检测用于无创性基因组分析的现实世界经验
Prerana Jha,Rohit Mishra,Asim Joshi et al.
Prerana Jha et al.
Background: Liquid biopsy assays are an important tool for non-invasive detection of genetic alterations, providing an effective alternative to traditional tissue biopsies. The study aimed to investigate the utility of ct...
Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances [0.03%]
循环肿瘤细胞的检测和监测技术提升：液体活检综合手段的新进展
Thanmayi Velpula,Viswanath Buddolla
Thanmayi Velpula
Liquid biopsy offers a minimally invasive method for detecting and monitoring cancer, with key biomarkers including circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs). Among these, CTCs provide dynamic i...
Circulating miRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis [0.03%]
泌尿生殖系统癌症的循环miRNA：早期检测和诊断的新进展
Annunziata Gaetana Cicatiello,Michele Musone,Silvestro Imperatore et al.
Annunziata Gaetana Cicatiello et al.
MicroRNAs (miRNAs) are noncoding, single-stranded RNAs molecules modulating gene expression thanks to their ability to bind mRNAs. Indeed, they regulate key processes for the proper functioning of the organism and affect the course of human...
Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL) [0.03%]
晚期BRAF突变黑色素瘤患者中循环肿瘤DNA监测的液体活检研究(LIQUID-MEL)
Martines Gianmarco,Palazzi Carolina,Monica Gregorio et al.
Martines Gianmarco et al.
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic melanoma, but a percentage of patients did not show benefit. Circulating tumor DNA (ctDNA) has emerged as a potential non-i...
The growing field of liquid biopsy and its Snowball effect on reshaping cancer management [0.03%]
液体活检方兴未艾及其对重塑癌症治疗模式的雪球效应
Roberto Borea,Carolina Reduzzi
Roberto Borea
Liquid biopsy (LB) has emerged as a transformative tool in oncology, providing a minimally invasive approach for tumor detection, molecular characterization, and real-time treatment monitoring. By analyzing circulating tumor DNA (ctDNA), ci...
Smoking induces different expression of miR-320b and miR-10b-5p in plasma extracellular vesicles of non-small cell lung cancer patients [0.03%]
吸烟通过诱导非小细胞肺癌患者血浆外泌体中miR-320b和miR-10b-5p的差异表达促进肿瘤发生发展
Markus Yovian Widjaja Lomanto,Septelia Inawati Wanandi,Achmad Mulawarman Jayusman et al.
Markus Yovian Widjaja Lomanto et al.
Background: Previous studies found that cigarette smoke (CS) exposure could induce NSCLC malignancy and miRNA dysregulation. Yet, the association of CS-induced miRNA dysregulation and NSCLC malignancy has not been clearly...
Veronica Aran
Veronica Aran
The prospects and limitations of liquid biopsy utilization for clinical practice in Taiwan [0.03%]
液体活检在台湾临床实践中应用的前景和局限性
Huei-Ying Li,Chun-Chuan Chang,Yu-Hsuan Yang et al.
Huei-Ying Li et al.
Objective: Liquid biopsy is a promising, non-invasive diagnostic tool for cancer, offering rapid and cost-effective genomic analysis. It provides a less invasive alternative to traditional tissue biopsies, with potential ...
Liquid biopsy for lung cancer: A cross section on the diagnostic routine experience of a referral Italian institution [0.03%]
肺癌的液体活检：意大利一家转诊机构诊断常规经验的横断面分析
Caterina de Luca,Gianluca Russo,Mariantonia Nacchio et al.
Caterina de Luca et al.
Background: Lung cancer is the leading cause of cancer death worldwide. Over the last decade, molecular testing of a growing number of predictive biomarkers has become mandatory in the management of NSCLC patients. Howeve...